No Data
FGEN FibroGen
Watchlist- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About FibroGen Company
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Revenue Breakdown
News
FibroGen/Astellas' EVRENZO (Roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice's VAFSEO (Vadadustat), Prepares for Launch in Early 2024.
Exton, Pennsylvania, Dec. 08, 2023 (GLOBE NEWSWIRE) -- EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021, securing its position by
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)
FibroGen: Q3 Earnings Snapshot
Comments
8/31 Watchlist ⚡️

ColumnsNavigating the Open Interest of Options on 6/27: Palantir Stock Rose Today, But Some Investors Remain Bearish on Its Prospects
The most decrease in the open interest today came to $FibroGen(FGEN.US$'s put option with a strike price of $10.00 and an e...


TOP WATCH 6/27 ⚡️⚡️

bottom?
ColumnsStocks with Notable Option Volatility: Microvision, Lexicon Pharmaceuticals and C3 AI.
Here are the notable stocks with the highest and lowest implied volatility.The $Microvision(MVIS.US$, $FibroGen(FGEN.US$, and $Lexicon Pharmaceuticals(LXRX.US$has the highest implied volatility of all stocks with a market ...


ColumnsStocks with Notable Option Volatility: PacWest, FibroGen and Aemetis
Here are the notable stocks with the highest and lowest implied volatility.
The$PacWest Bancorp(PACW.US)$, $FibroGen(FGEN.US$, and $Aemetis(AMTX.US$ has the highest implied volatility of all stocks with a market cap of over 100 million.
Pacwe...


ColumnsUS Top Rating Updates on 1/31: BAC, DLTR, EW, INCY and More
William Blair analyst Andy Hsieh upgraded $FibroGen(FGEN.US$ to Outperform from Market Perform following a deep dive on the potential of pamrevlumab, the company's wholly owned monoclonal antibody against connective tissue growth factor, which is being evaluated in the treatment of idiopathic pulmonary fibrosis, or IPF, locally advanced pancreatic cancer, or LAP...

ColumnsToday's pre-market stock movers: NVAX, MRNA, NCLH, MU and more
In reaction to earnings/guidance:
• $GoodRx(GDRX.US$ +38.5%,$EDGIO(EGIO.US$ +13.5%,$Lemonade(LMND.US$ +10.7%,$Desktop Metal(DM.US$ +8.5%,$ShockWave Medical(SWAV.US$ +8.2%,$Pubmatic(PUBM.US$ +8.1%,$Olaplex(OLPX.US$ +7%,$Vivid Seats(SEAT.US$ +6.4%,$Noble(NE.US$ +6.3%,$Aspen Technology(AZPN.US$ +5.4%,$AAON Inc(AAON.US$ +5%,$Hudbay Minerals(HBM.US$ +5%,$Vivint Smart Home(VVNT.US$ +4.9%,$Vivint Smart Home(VVNT.US$ +4...